Copyright ©The Author(s) 2015.
World J Pharmacol. Mar 9, 2015; 4(1): 17-30
Published online Mar 9, 2015. doi: 10.5497/wjp.v4.i1.17
Table 2 Pharmacokinetic parameters for levomilnacipran and vortioxetine[3,20,21,24]
Bioavailability92%75% ± 9%
Tmax6-8 h3-16 h
Volume of distribution387-473 L2400 L
MetabolismOxidation (primarily through CYP3A4), glucuronidationOxidation (primarily through CYP2D6), glucuronidation
Elimination58% urine50% urine, 26% feces
Clearance21-29 L/h38 L/h
Half-life12 h57-66 h
Protein binding22%98%-99%